White Papers

White Paper Management

When the U.S. Food and Drug Administration gave final approval in May 2019 to alpelsib, a new drug manufactured by Novartis Pharmaceutical, it was hailed by the company as “the first ever treatment specifically for HR+/HER2- advanced breast cancer that specifically addresses the needs of the patients living with this mutation. The drug was quickly brought to market under the brand name “Piqray,” at a cost of $15,500 for a 28-day supply. This example illustrates the critically important sector of the pharmaceutical market known as “specialty pharmacy” – a small but growing number of medications that are highly complex, very costly, and targeted at a small number of patients.


Download